Asenapine Maleate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Asenapine Maleate |
| DrugBank ID | DB06216 |
| Brand Names (EU) | Sycrest |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99.99% | DL |
| 2 | schizophrenia | 99.90% | DL |
| 3 | bipolar disorder | 99.80% | DL |
| 4 | retinal dystrophy with or without extraocular anomalies | 99.77% | DL |
| 5 | congenital disorder of glycosylation with defective fucosylation | 99.75% | DL |
| 6 | hydranencephaly (disease) | 99.74% | DL |
| 7 | syndromic myopia | 99.70% | DL |
| 8 | myopia X-linked | 99.69% | DL |
| 9 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.68% | DL |
| 10 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.68% | DL |
| 11 | myopia 26, X-linked, female-limited | 99.65% | DL |
| 12 | atypical glycine encephalopathy | 99.58% | DL |
| 13 | major affective disorder | 99.57% | DL |
| 14 | distal 17p13.3 microdeletion syndrome | 99.56% | DL |
| 15 | schizophreniform disorder | 99.24% | DL |
| 16 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 99.21% | DL |
| 17 | Malan overgrowth syndrome | 99.12% | DL |
| 18 | trichotillomania | 98.80% | DL |
| 19 | Tourette syndrome | 97.74% | DL |
| 20 | anxiety disorder | 97.12% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.